|Mr. Robert A. Berman||CEO & Director||398.67k||N/A||1963|
|Mr. Robert A. Rankin||CFO, Sec. & Treasurer||238.45k||N/A||1953|
|Dr. Benedict Broennimann M.D.||Chief Medical Officer of Outside of United States||240k||N/A||1957|
|Dr. Marc H. Glickman||Sr. VP & Chief Medical Officer||362.64k||N/A||1949|
|Mr. Warren Hancock||Co-founder||N/A||N/A||N/A|
Hancock Jaffe Laboratories, Inc., a development stage company, develops and sells biological based tissue solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. The company develops and manufactures bioprosthetic implantable devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat chronic venous insufficiency; the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries; and the Bioprosthetic Heart Valve, a porcine based heart valve designed to function like a native heart valve used for pediatric heart valve recipients. It also provides research, development, and contract manufacturing services. Hancock Jaffe Laboratories, Inc. was founded in 1987 and is based in Irvine, California.
Hancock Jaffe Laboratories, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.